Long-term Functional Alterations Following Prenatal GLP-1R Activation

Overview

Journal Neurotoxicol Teratol

Specialties Neurology
Toxicology

Date 2021 Apr 17

PMID 33864929

Citations 9

Authors

Devon L Graham

Haley S Madkour

Brenda L Noble

Chris Schatschneider

Gregg D Stanwood

Affiliations

Soon will be listed here.

Abstract

Evidence supporting the use of glucagon-like peptide-1 (GLP-1) analogues to pharmacologically treat disorders beyond type 2 diabetes and obesity is increasing. However, little is known about how activation of the GLP-1 receptor (GLP-1R) during pregnancy affects maternal and offspring outcomes. We treated female C57Bl/6 J mice prior to conception and throughout gestation with a long-lasting GLP-1R agonist, Exendin-4. While GLP-1R activation has significant effects on food and drug reward, depression, locomotor activity, and cognition in adults, we found few changes in these domains in exendin-4-exposed offspring. Repeated injections of Exendin-4 had minimal effects on the dams and may have enhanced maternal care. Offspring exposed to the drug weighed significantly more than their control counterparts during the preweaning period and demonstrated alterations in anxiety-like outcomes, which indicate a developmental role for GLP-1R modulation in the stress response that may be sex-specific.

Citing Articles

Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.

Price S, Nankervis A Arch Gynecol Obstet. 2025; .

PMID: 39762582 DOI: 10.1007/s00404-024-07849-9.

Bile acid signalling and its role in anxiety disorders.

Chen S, Shao Q, Chen J, Lv X, Ji J, Liu Y Front Endocrinol (Lausanne). 2023; 14:1268865.

PMID: 38075046 PMC: 10710157. DOI: 10.3389/fendo.2023.1268865.

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.

Muller D, Stenvers D, Malekzadeh A, Holleman F, Painter R, Siegelaar S Front Endocrinol (Lausanne). 2023; 14:1215356.

PMID: 37881498 PMC: 10597691. DOI: 10.3389/fendo.2023.1215356.

Insulin-sensitizing agents for infertility treatment in woman with polycystic ovary syndrome: a narrative review of current clinical practice.

Sparic R, Andjic M, Rakic A, Bjekic-Macut J, Livadas S, Kontic-Vucinic O Hormones (Athens). 2023; 23(1):49-58.

PMID: 37792213 DOI: 10.1007/s42000-023-00494-y.

Glucagon-like peptide-1 receptor agonists and safety in the preconception period.

Minis E, Stanford F, Mahalingaiah S Curr Opin Endocrinol Diabetes Obes. 2023; 30(6):273-279.

PMID: 37678163 PMC: 10615799. DOI: 10.1097/MED.0000000000000835.

References

Graham D, Erreger K, Galli A, Stanwood G . GLP-1 analog attenuates cocaine reward. Mol Psychiatry. 2012; 18(9):961-2. PMC: 3700649. DOI: 10.1038/mp.2012.141. View

Younes S, Maeda K, Sasser J, Ryan M . The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension. Am J Physiol Heart Circ Physiol. 2019; 318(1):H72-H77. PMC: 6985807. DOI: 10.1152/ajpheart.00486.2019. View

Tatarkiewicz K, Sablan E, Polizzi C, Villescaz C, Parkes D . Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. Am J Physiol Regul Integr Comp Physiol. 2014; 306(7):R490-8. DOI: 10.1152/ajpregu.00495.2013. View

Lencioni C, Resi V, Romero F, Lupi R, Volpe L, Bertolotto A . Glucagon-like peptide-1 secretion in women with gestational diabetes mellitus during and after pregnancy. J Endocrinol Invest. 2011; 34(9):e287-90. DOI: 10.3275/7799. View

Gulec G, Isbil-Buyukcoskun N, Kahveci N . Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat. Neuropeptides. 2010; 44(4):285-91. DOI: 10.1016/j.npep.2010.02.002. View

Nylander M, Frossing S, Clausen H, Kistorp C, Faber J, Skouby S . Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017; 35(1):121-127. DOI: 10.1016/j.rbmo.2017.03.023. View

Brown E, Cuthbertson D, Wilding J . Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018; 100:61-67. DOI: 10.1016/j.peptides.2017.12.009. View

Egecioglu E, Engel J, Jerlhag E . The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013; 8(10):e77284. PMC: 3799694. DOI: 10.1371/journal.pone.0077284. View

Glotfelty E, Olson L, Karlsson T, Li Y, Greig N . Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. Expert Opin Investig Drugs. 2020; 29(6):595-602. PMC: 10477949. DOI: 10.1080/13543784.2020.1764534. View

10.

Werner E, Gustafsson H, Lee S, Feng T, Jiang N, Desai P . PREPP: postpartum depression prevention through the mother-infant dyad. Arch Womens Ment Health. 2015; 19(2):229-42. PMC: 4738166. DOI: 10.1007/s00737-015-0549-5. View

11.

Jaramillo T, Speed H, Xuan Z, Reimers J, Liu S, Powell C . Altered Striatal Synaptic Function and Abnormal Behaviour in Shank3 Exon4-9 Deletion Mouse Model of Autism. Autism Res. 2015; 9(3):350-75. PMC: 4857590. DOI: 10.1002/aur.1529. View

12.

Clancy B, Finlay B, Darlington R, Anand K . Extrapolating brain development from experimental species to humans. Neurotoxicology. 2007; 28(5):931-7. PMC: 2077812. DOI: 10.1016/j.neuro.2007.01.014. View

13.

Kandzija N, Zhang W, Motta-Mejia C, Mhlomi V, McGowan-Downey J, James T . Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus. J Extracell Vesicles. 2019; 8(1):1617000. PMC: 6534242. DOI: 10.1080/20013078.2019.1617000. View

14.

Hayes M, De Jonghe B, Kanoski S . Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav. 2010; 100(5):503-10. PMC: 2886183. DOI: 10.1016/j.physbeh.2010.02.029. View

15.

Kinzig K, DAlessio D, Herman J, Sakai R, Vahl T, Figueiredo H . CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci. 2003; 23(15):6163-70. PMC: 6740553. View

16.

Golub M, Sobin C . Statistical modeling with litter as a random effect in mixed models to manage "intralitter likeness". Neurotoxicol Teratol. 2019; 77:106841. DOI: 10.1016/j.ntt.2019.106841. View

17.

Clancy B, Darlington R, Finlay B . Translating developmental time across mammalian species. Neuroscience. 2001; 105(1):7-17. DOI: 10.1016/s0306-4522(01)00171-3. View

18.

Eakin K, Li Y, Chiang Y, Hoffer B, Rosenheim H, Greig N . Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One. 2013; 8(12):e82016. PMC: 3847068. DOI: 10.1371/journal.pone.0082016. View

19.

Erreger K, Davis A, Poe A, Greig N, Stanwood G, Galli A . Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav. 2012; 106(4):574-8. PMC: 3348974. DOI: 10.1016/j.physbeh.2012.03.014. View

20.

Holscher C . Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology. 2018; 136(Pt B):251-259. DOI: 10.1016/j.neuropharm.2018.01.040. View